Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · Real-Time Price · USD
5.28
-0.02 (-0.47%)
Aug 14, 2025, 2:06 PM - Market open
Puma Biotechnology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Puma Biotechnology stock has a target of 7.00, which predicts a 32.70% increase from the current stock price of 5.28.
Price Target: $7.00 (+32.70%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 28, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Puma Biotechnology is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +32.70% | Feb 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +32.70% | Dec 23, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +32.70% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +32.70% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +32.70% | Aug 2, 2024 |
Financial Forecast
Revenue This Year
222.16M
from 230.47M
Decreased by -3.60%
Revenue Next Year
221.20M
from 222.16M
Decreased by -0.43%
EPS This Year
0.48
from 0.62
Decreased by -22.13%
EPS Next Year
0.40
from 0.48
Decreased by -17.32%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 231.0M | 247.4M | 261.0M | ||
| Avg | 222.2M | 221.2M | 224.6M | ||
| Low | 212.1M | 193.1M | 192.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.2% | 11.4% | 18.0% | ||
| Avg | -3.6% | -0.4% | 1.5% | ||
| Low | -8.0% | -13.1% | -13.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.72 | 0.53 | 0.70 | ||
| Avg | 0.48 | 0.40 | 0.47 | ||
| Low | 0.27 | 0.17 | 0.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 16.0% | 8.7% | 76.2% | ||
| Avg | -22.1% | -17.3% | 17.5% | ||
| Low | -55.7% | -64.7% | -23.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.